Company
Headquarters: Changsha, China
Employees: 911
CN¥11.83 Billion
CNY as of Jan. 1, 2025
US$1.62 Billion
| Company | Market Cap (USD) |
|---|---|
| Intuitive | $216.79 B |
| EssilorLuxottica SA | $116.96 B |
| Becton, Dickinson and Company | $69.74 B |
| HOYA Corp | $45.26 B |
| Alcon Inc. | $41.55 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Sansure Biotech Inc. develops and sells upstream nucleic acid extraction kits, real time PCR diagnostic and research kits, and fluorescence systems in China and internationally. The company offers novel coronavirus nucleic acid diagnostic kits; viral hepatitis and AIDS, blood screening, and extraction kits; cancer-related biomarkers; and kits for respiratory tract diseases, STDs, digestive tract diseases, prenatal and postnatal care, and genetic diseases, as well as instruments and other consumables. It serves hospitals and laboratories. The company was founded in 2008 and is based in Changsha, China.
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | CN¥1.41 B |
| EBITDA | CN¥264.3 M |
| Gross Profit TTM | CN¥1.09 B |
| Profit Margin | 18.44% |
| Operating Margin | -6.52% |
| Quarterly Revenue Growth | 54.10% |
Sansure Biotech, Inc. has the following listings and related stock indices.
Stock: SSE: 688289 wb_incandescent